Navigation Links
Researchers pinpoint genetic pathways involved in breast cancer
Date:3/3/2011

EAST LANSING, Mich. Using recent advances in genomics, researchers have uncovered a genetic pathway that affects the development of breast cancer, work that could help predict which patients are at risk of relapse for the disease.

By studying which genes are expressed or "turned on" in breast cancer, research led by Michigan State University's Eran Andrechek uncovered a role for several members of the E2F family of genes, which control cell division and growth.

Specifically, Andrechek's team found the activation of the specific gene E2F2 was associated with a higher probability of breast cancer relapse in humans. The research team, using rodent models, also found that removing the E2F2 gene significantly decreased the likelihood of a tumor.

The findings, to be published in the journal Cancer Research, are available online now.

"Genomic signatures how genes interact and via what pathways are a rapidly growing and a powerful method to analyze specific genes in the development, recurrence and spread of breast cancer," said Andrechek, an assistant professor in the MSU Department of Physiology and lead author of the paper.

After identifying which genes are being activated, physicians can tailor treatments for breast cancer and other diseases to individuals with certain genetic makeups. For example, breast cancer patients with over-expression of a gene called HER2 are currently treated with the antibody Herceptin, which specifically targets the cells over-expressing HER2.

"With personalized medicine, we can use predictions of how genes will interact, and based on that we can make better use of existing treatments that will have more of an impact," Andrechek said.

As part of the research, Andrechek and his team focused on tumors initiated by Myc, a gene that is amplified in 15 percent of all human breast cancer cases. The team then analyzed the tumors to test which pathways were critical to tumor growth, first in computer models and then in rodent models.

In addition to the discovery of E2F2's role in tumor incidence and relapse, the research also revealed the gene was critical for the development of a type of basal tumor. These tumors are similar to the so-called "triple negative tumors" in human breast cancer that are more prevalent among blacks and are much more difficult to treat.

The article can be viewed online at http://cancerres.aacrjournals.org/content/early/2011/01/18/0008-5472.CAN-10-2386.abstract. Other contributing authors included Kenichiro Fujiwara, Inez Yuwanita, and Daniel Hollern.

An extension of Andrechek's work has recently been funded by the Elsa U. Pardee Foundation a Michigan organization that has given more than $113 million in grants for cancer research to explore therapy options based on genomic profiles.

"We want to examine how we can design therapies for specific tumor types by combining genomics and current medicines," he said. "We feel this holds great promise for personalized cancer therapy."


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related medicine news :

1. Penn researchers find new role for cancer protein p53
2. UCSF researchers uncover hormone pathway to fatty liver disease
3. Researchers pinpoint patients who receive greatest benefit from heart failure treatment
4. IDIBELL researchers discover a substance against the dark genome of cancer
5. Wayne State University researchers publish results settling multiple sclerosis debate
6. E-health must be a priority, researchers say
7. Mayo Clinic researchers confirm value of therapeutic hypothermia after cardiac arrest
8. Mayo researchers, Rochester educators, students to present at science conference
9. Researchers work at the frontiers of islet cell transplantation
10. Brain Appears to Be a Task Machine, Researchers Say
11. Researchers develop outline that may help weigh benefits of new imaging technologies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers pinpoint genetic pathways involved in breast cancer
(Date:12/8/2016)... , ... December 08, 2016 , ... Vida ... an $18M Series B led by Canvas Ventures . Other investors include Nokia ... scale its mobile platform to serve more consumers who are managing chronic conditions ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets ... report to their offering. ... The global chromatography market to grow ... Global Chromatography Market 2016-2020, has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/8/2016)... 8, 2016 According to ... by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), ... Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global ... has witnessed healthy growth during the last decade, ... of 4.3% between 2016 and 2021 to reach ...
(Date:12/8/2016)... 8, 2016  Agenovir Corporation, a company using ... therapeutics, today announced that it appointed Dirk ... a member of the board of directors. ... a deep background in both founding and building ... Agenovir, co-president of Chan Zuckerberg  Biohub and ...
Breaking Medicine Technology: